JPT - Key Persons
Aurélien Claeyssen has been managing director of JPT Peptide Technologies since January 2024. He holds a Masters degree in Biotechnology and Management from the Faculty of Pharmacy of Grenoble and the Grenoble Management School (France). After 3 years as a business developer in life sciences, he co-founded Smartox in 2013, a peptide-based drug discovery company, and SB-PEPTIDE in 2016, a peptide CDMO company. He served as Chief Commercial Officer and Board Member.
Dr. Holger Wenschuh has been Managing Director at JPT Peptide Technologies from 2004 to 2023. Before, he served as Business Unit Manager at Jerini AG and Managing Director at Chemotopix GmbH. Dr. Wenschuh studied Chemistry at the Friedrich-Schiller-University in Jena, Germany, and obtained his PhD in Organic Chemistry at the Institute of Molecular Pharmacology in Berlin, Germany. He worked at the University of Massachusetts and Perseptive Biosystems, USA and from 1995 to 1997, headed the Peptide Unit at the Max-Planck-Institute of Infection Biology in Berlin. Dr. Wenschuh is author and co-author of numerous publications, co-inventor on several patents and editorial board member of the International Journal of Peptide Research and Therapeutics.
Sean Marett has 30 years of international experience in the management of operations, sales and marketing licensing, M&A and new product development.
He has worked for large pharmaceutical companies such as GSK and Pfizer and done contract research, development and manufacturing for companies such as Evotec and NextPharma. He has successfully executed a number of licensing transactions with large pharmaceutical companies, completed large pharmaceutical service deals and negotiated several M&A transactions. Sean Marett is non-executive director of KWS BioTest Ltd and a member of the investment committee of Mann BioInvest Ltd.